Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ...

Top line data from the VANTAGE study of volixibat in primary biliary cholangitis are expected in the first quarter of 2027.

In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...

Mirum Pharmaceuticals is prepping for a new FDA approval application after its small molecule volixibat successfully ...

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with PSC on May 4, 2026 ...

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing ...

A study of unprecedented scale has led researchers to identify four previously unknown genetic risk locations for primary sclerosing cholangitis, a liver disease that lacks effective medical therapy.

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree ...

According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as LB-P8 ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an ...

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

According to the results of a new international study, there may be a role for insulin-like growth factor-binding protein 4 (IGFBP4) in facilitating the interaction between macrophages and injured ...